Condition category
Circulatory System
Date applied
12/10/2004
Date assigned
12/10/2004
Last edited
07/08/2007
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr Cornel Pater

ORCID ID

Contact details

Hans-Boeckler Allee 20
Hannover
30173
Germany
+49 (0)511 857 2074
cornel.pater@solvay.com

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

S171.3.012

Study information

Scientific title

Acronym

ASTRID (Antihypertensive treatment of Systolic/diastolic hypertension comparing Teveten and Ramipril and type 2 Diabetics)

Study hypothesis

Not provided at time of registration

Ethics approval

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

GP practices

Trial type

Treatment

Patient information sheet

Condition

Essential Hypertension grade I and II

Intervention

Single, double- and triple- combination antihypertensive therapy, active controlled (monotherapy [eprosartan versus ramipril] followed by addition of hydrochlorothiazide as second agent and moxonidine as a third agent).

Intervention type

Other

Phase

Not Specified

Drug names

Primary outcome measures

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall trial start date

01/01/2004

Overall trial end date

01/01/2006

Reason abandoned

Eligibility

Participant inclusion criteria

Investigative centers from eight European countries and Canada (primary and secondary care) targeting patients with grade I - II hypertension and associated diabetes mellitus type 2. Goal blood pressure (BP) targeted: below 130/80 mmHg.

Participant type

Patient

Age group

Not Specified

Gender

Not Specified

Target number of participants

Not provided at time of registration

Participant exclusion criteria

Not provided at time of registration

Recruitment start date

01/01/2004

Recruitment end date

01/01/2006

Locations

Countries of recruitment

Germany, United Kingdom

Trial participating centre

Hans-Boeckler Allee 20
Hannover
30173
Germany

Sponsor information

Organisation

Solvay Pharmaceuticals (Germany)

Sponsor details

Hans-Boeckler Allee 20
Hannover
30173
Germany

Sponsor type

Industry

Website

Funders

Funder type

Industry

Funder name

GPS Solvay Pharmaceuticals

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Protocol in: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15461784

Publication citations

  1. Protocol

    Pater C, Bhatnagar D, Berrou JP, Luszick J, Beckmann K, A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design [ISRCTN55725285]., Curr Control Trials Cardiovasc Med, 2004, 5, 1, 9, doi: 10.1186/1468-6708-5-9.

Additional files

Editorial Notes